Defense World
04 Apr 2026, 05:05 UTC · 23w ago
Verdict
Headline takes no side. We score AKBA +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 74% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Akebia is advancing praliciguat for the treatment of focal segmental glomerulosclerosis (FSGS).
So whatSuccess in a specific kidney disease indication represents a significant expansion of the company's addressable market and valuation.
More positive than 76% of claims this week
The company is developing AKB-097 (abribafisp) as a tissue-targeted complement inhibitor for complement-mediated kidney diseases.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 64% of claims this week
Akebia is progressing AKB-9090 to treat cardiac surgery-associated acute kidney injury (CSA-AKI).
More positive than 64% of claims this week
Akebia is focusing its strategy on expanding the commercial franchise for Vafseo.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 74% of ticker scores this week
The company presented a clear growth strategy for its commercial franchise and outlined a promising pipeline of three kidney disease programs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
1d ago
−33.6%
Price is moving against the score
$0.9157 vs $1.38 close before publication (Apr 2) · not market-adjusted
AKBA chart →
